Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Change in Cash (2016 - 2025)

Iradimed (IRMD) has disclosed Change in Cash for 13 consecutive years, with $3.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 10.81% to $3.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.8 million, a 3.43% decrease, with the full-year FY2024 number at $2.5 million, up 130.15% from a year prior.
  • Change in Cash was $3.5 million for Q3 2025 at Iradimed, up from $2.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $4.4 million in Q2 2021 to a low of -$15.2 million in Q1 2023.
  • A 5-year average of $339864.4 and a median of $2.7 million in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: soared 430.62% in 2021, then tumbled 1676.35% in 2022.
  • Iradimed's Change in Cash stood at $3.6 million in 2021, then tumbled by 34.71% to $2.4 million in 2022, then grew by 27.37% to $3.0 million in 2023, then tumbled by 83.0% to $512856.0 in 2024, then surged by 588.37% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Change in Cash are $3.5 million (Q3 2025), $2.7 million (Q2 2025), and -$1.9 million (Q1 2025).